Predictmedix Announces a
Purchase Order for Safe Entry's Fit for Duty Screening in the
Defence Sector
-
DefSpace, a
global platform for Defence, Space and Aerospace will lease four
Safe Entry Stations over four-year term primarily utilizing Safe
Entry's impairment detection screening
-
Each of the four Safe
Entry Station's to generate $2500 per month in recurring revenue
for an initial four-year term, approximating a total of
$500,000
-
The Global workplace safety market is expected to generate $39
billion by 20311
Toronto, Ontario, March 6,
2023 – InvestorsHub NewsWire -- Predictmedix Inc.
("Predictmedix" or the "Company") (CSE: PMED) (OTCQB: PMEDF) (FRA:3QP), an emerging provider of rapid
health screening solutions powered by a proprietary artificial
intelligence (AI), today announced a purchase agreement with
Defspace, an India based global platform for defence, space and
aerospace for the company's Safe Entry's Fit for Duty screening.
Defspace will lease four Safe Entry Stations which will be used by
their clients in the defence and aerospace sector to screen their
workforce for signs of impairment – an issue that hinders
productivity and threatens health and safety across all operations.
The total value of the purchase order is approximately $500,000 for
the entire term.
DefSpace operates an
exclusive global platform for Defence, Space and Aerospace. The
platform offers secured and authorised connections between buyers
and sellers, Investment opportunities, job opportunities and many
services that add significant value to companies who are already
working in Defence, Space and Aerospace Sector or for those just
entering the field. "The technology developed by Predictmedix
addresses a key unmet need in several sectors which not only
includes healthcare and workplace but also the defence and
aerospace industry. We are excited and confident of the positive
impact the technology will be making in the defence sector",
commented Anushka Shah, Founder & Director at
DefSpace.
"Impairment is a huge
concern for many industries and sectors worldwide. Safe Entry's Fit
for Duty screening ensures workforces are fit for duty by screening
individuals key vital signs. When an individual is impaired by
alcohol or cannabis, Safe Entry will let you know. The
multi-spectral cameras and AI-algorithms scan for a multitude of
physiological factors and behaviors – indicating intoxication,
impairment, sickness, and extreme fatigue. Safe Entry is a strong
line of defence against encumbered employees, and we are excited to
announce our first contract in the defence sector," commented Dr.
Rahul Kushwah, Chief Operating Officer at Predictmedix.
"We are excited to be
moving ahead with commercialization in the defence space with
DefSpace and are seeing tremendous interest across multiple
verticals", commented Guru Bakshish Singh Sehgal, Head of Indian
operations at Predictmedix.
1https://www.alliedmarketresearch.com/workplace-safety-market-A31780#:~:text=The%20global%20workplace%20safety%20market,home%20culture%20across%20the%20globe.
About Predictmedix
Inc.
Predictmedix (CSE: PMED)
(OTCQB: PMEDF) (FRA:3QP) is an emerging provider of rapid health
screening and remote patient care solutions globally. The Company's
Safe Entry Stations – powered by a proprietary artificial
intelligence (AI) – use multispectral cameras to analyze
physiological data patterns and predict a variety of health issues
including infectious diseases such as COVID-19, impairment by drugs
or alcohol, fatique or various mental illnesses. Predictmedix's
proprietary remote patient care platform empowers medical
professionals with a suite of AI-powered tools to improve patient
health outcomes. To learn more, please visit our website at
www.Predictmedix.com or follow us on Twitter, Instagram or
LinkedIn.
Public Relations
Contact
For further media
information or to set up an interview, please contact:
Nelson Hudes
Hudes Communications
International
(905) 660 9155
Nelson@hudescommunications.com
Dr. Rahul
Kushwah
(647) 889 6916
Caution Regarding
Forward-Looking Information:
This news release may
contain forward-looking statements and information based on current
expectations. These statements should not be read as guarantees of
future performance or results of the Company. Such statements
involve known and unknown risks, uncertainties and other factors
that may cause actual results, performance or achievements to be
materially different from those implied by such statements.
Although such statements are based on management's reasonable
assumptions, there can be no assurance that such assumptions will
prove to be correct. We assume no responsibility to update or
revise them to reflect new events or circumstances. The Company's
securities have not been registered under the U.S. Securities Act
of 1933, as amended (the "U.S. Securities Act"), or applicable
state securities laws, and may not be offered or sold to, or for
the account or benefit of, persons in the United States or "U.S.
Persons", as such term is defined in Regulations under the U.S.
Securities Act, absent registration or an applicable exemption from
such registration requirements. This press release shall not
constitute an offer to sell or the solicitation of an offer to buy
nor shall there be any sale of the securities in the United States
or any jurisdiction in which such offer, solicitation or sale would
be unlawful. Additionally, there are known and unknown risk factors
which could cause the Company's actual results, performance or
achievements to be materially different from any Page 4 of 4 future
results, performance or achievements expressed or implied by the
forward-looking information contained herein, such as, but not
limited to dependence on obtaining regulatory approvals; the
ability to obtain intellectual property rights related to its
technology; limited operating history; general business, economic,
competitive, political, regulatory and social uncertainties, and in
particular, uncertainties related to COVID-19; risks related to
factors beyond the control of the Company, including risks related
to COVID-19; risks related to the Company's shares, including price
volatility due to events that may or may not be within such party's
control; reliance on management; and the emergency of additional
competitors in the industry.
All forward-looking
information herein is qualified in its entirety by this cautionary
statement, and the Company disclaims any obligation to revise or
update any such forward-looking information or to publicly announce
the result of any revisions to any of the forward-looking
information contained herein to reflect future results, events or
developments, except required by law.
Disclaimer: "The Company
is not making any express or implied claims that its product has
the ability to diagnose, eliminate, cure or contain the COVID-19
(or SARS-2 Coronavirus) at this time."
THE CANADIAN SECURITIES
EXCHANGE HAS NOT REVIEWED NOR DOES IT ACCEPT RESPONSIBILITY FOR THE
ADEQUACY OR ACCURACY OF THIS RELEASE.
Predictmedix Al (CSE:PMED)
Gráfica de Acción Histórica
De Nov 2024 a Dic 2024
Predictmedix Al (CSE:PMED)
Gráfica de Acción Histórica
De Dic 2023 a Dic 2024
